标题
Histone Deacetylase Inhibition in Non-small Cell Lung Cancer: Hype or Hope?
作者
关键词
-
出版物
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2020-10-09
DOI
10.3389/fcell.2020.582370
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Overcoming acquired resistance of epidermal growth factor receptor‐mutant non–small‐cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589)
- (2020) Hongjing Zang et al. CANCER
- Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes
- (2020) Nicole Kiweler et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Epigenetic therapy inhibits metastases by disrupting premetastatic niches
- (2020) Zhihao Lu et al. NATURE
- Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater
- (2019) Martin Reck et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
- (2019) Debarati Banik et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
- (2019) Jhanelle E. Gray et al. CLINICAL CANCER RESEARCH
- N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PDL-1 expression
- (2019) Samir Mehndiratta et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double‐positive lung cancer
- (2019) Shinji Takeuchi et al. CANCER SCIENCE
- Histone deacetylase 11 inhibition promotes breast cancer metastasis from lymph nodes
- (2019) Patrick L. Leslie et al. Nature Communications
- Inhibition of HDAC6 Attenuates Tumor Growth of Non-Small Cell Lung Cancer
- (2019) Brian Deskin et al. Translational Oncology
- Targeting histone deacetylase SIRT1 selectively eradicates EGFR TKI-resistant cancer stem cells via regulation of mitochondrial oxidative phosphorylation in lung adenocarcinoma
- (2019) Jiangtao Sun et al. NEOPLASIA
- Histone Deacetylase Inhibitors as a Novel Targeted Therapy Against Non-small Cell Lung Cancer: Where Are We Now and What Should We Expect?
- (2018) ANTICANCER RESEARCH
- Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
- (2018) Leena Gandhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi
- (2018) Amila Suraweera et al. Frontiers in Oncology
- Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
- (2018) Luis Paz-Ares et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vorinostat and Concurrent Stereotactic Radiosurgery for Non-Small Cell Lung Cancer Brain Metastases: A Phase 1 Dose Escalation Trial
- (2017) Clara Y.H. Choi et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Phase I study of LBH589 in combination with erlotinib for advanced aerodigestive tract cancers.
- (2017) J. E. Gray et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone deacetylase inhibitors for cancer therapy: An evolutionarily ancient resistance response may explain their limited success
- (2016) John A. Halsall et al. BIOESSAYS
- HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma
- (2016) Hong Zheng et al. CLINICAL CANCER RESEARCH
- Take two: Combining immunotherapy with epigenetic drugs to tackle cancer
- (2016) Karen Weintraub NATURE MEDICINE
- Targeting HDAC with a novel inhibitor effectively reverses paclitaxel resistance in non-small cell lung cancer via multiple mechanisms
- (2016) L Wang et al. Cell Death & Disease
- HDAC inhibitors with PD-1 blockade: a promising strategy for treatment of multiple cancer types?
- (2016) Amer A Beg et al. Epigenomics
- Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
- (2016) Valsamo Anagnostou et al. Cancer Discovery
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- The synergistic effects of DNA-damaging drugs cisplatin and etoposide with a histone deacetylase inhibitor valproate in high-risk neuroblastoma cells
- (2015) TOMAS GROH et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Epigenetic Modulation with HDAC Inhibitor CG200745 Induces Anti-Proliferation in Non-Small Cell Lung Cancer Cells
- (2015) Sung-Min Chun et al. PLoS One
- Alterations of immune response of non-small cell lung cancer with Azacytidine
- (2015) John Wrangle et al. Oncotarget
- Expression of Class I Histone Deacetylases Indicates Poor Prognosis in Endometrioid Subtypes of Ovarian and Endometrial Carcinomas
- (2015) Wilko Weichert et al. NEOPLASIA
- The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
- (2014) C. Costa et al. CLINICAL CANCER RESEARCH
- Dysregulated Class I histone deacetylases are indicators of poor prognosis in multiple myeloma
- (2014) Sridurga Mithraprabhu et al. Epigenetics
- Suberoylanilide hydroxamic acid radiosensitizes tumor hypoxic cells in vitro through the oxidation of nitroxyl to nitric oxide
- (2014) Yuval Samuni et al. FREE RADICAL BIOLOGY AND MEDICINE
- Targeting Histone Deacetylases for Cancer Therapy: From Molecular Mechanisms to Clinical Implications
- (2014) Zhiming Li et al. International Journal of Biological Sciences
- Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation
- (2014) Kazutoshi Isobe et al. Journal of Thoracic Oncology
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
- (2014) K. Kim et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A histone deacetylase inhibitor YCW1 with antitumor and antimetastasis properties enhances cisplatin activity against non-small cell lung cancer in preclinical studies
- (2013) Wei-Jan Huang et al. CANCER LETTERS
- Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy
- (2013) Duc Do et al. International Journal of Nanomedicine
- Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer
- (2013) Darryl T. Martin et al. Nanomedicine-Nanotechnology Biology and Medicine
- Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
- (2013) J S Riley et al. Cell Death & Disease
- Randomized Phase II Trial of Erlotinib With and Without Entinostat in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed on Prior Chemotherapy
- (2012) Samir E. Witta et al. JOURNAL OF CLINICAL ONCOLOGY
- Histone Deacetylase Inhibitors in Non–Small-Cell Lung Cancer
- (2012) Samir Witta Journal of Thoracic Oncology
- Playing the End Game: DNA Double-Strand Break Repair Pathway Choice
- (2012) J. Ross Chapman et al. MOLECULAR CELL
- A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer
- (2012) King Pan Ng et al. NATURE MEDICINE
- Mitochondrial Apoptosis and FAK Signaling Disruption by a Novel Histone Deacetylase Inhibitor, HTPB, in Antitumor and Antimetastatic Mouse Models
- (2012) Jiunn-Min Shieh et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancer cells
- (2011) Chien-Te Li et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2011) Yoshihiro Minamiya et al. LUNG CANCER
- Synergistic Antitumor Effects of Novel HDAC Inhibitors and Paclitaxel In Vitro and In Vivo
- (2011) Valentina Zuco et al. PLoS One
- BIM Expression in Treatment-Naive Cancers Predicts Responsiveness to Kinase Inhibitors
- (2011) A. C. Faber et al. Cancer Discovery
- Combination Epigenetic Therapy Has Efficacy in Patients with Refractory Advanced Non-Small Cell Lung Cancer
- (2011) R. A. Juergens et al. Cancer Discovery
- Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
- (2010) Cliona Grant et al. Expert Review of Anticancer Therapy
- Vorinostat (NSC# 701852) in Patients with Relapsed Non-small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
- (2010) Anne M. Traynor et al. Journal of Thoracic Oncology
- Human HDAC1 and HDAC2 function in the DNA-damage response to promote DNA nonhomologous end-joining
- (2010) Kyle M Miller et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Anti-Tumor Effect in Human Lung Cancer by a Combination Treatment of Novel Histone Deacetylase Inhibitors: SL142 or SL325 and Retinoic Acids
- (2010) Shaoteng Han et al. PLoS One
- Histone Deacetylase Inhibitors Downregulate Checkpoint Kinase 1 Expression to Induce Cell Death in Non-Small Cell Lung Cancer Cells
- (2010) William Brazelle et al. PLoS One
- Strong expression of HDAC3 correlates with a poor prognosis in patients with adenocarcinoma of the lung
- (2010) Yoshihiro Minamiya et al. TUMOR BIOLOGY
- A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways
- (2009) Jung Jin Hwang et al. ANTI-CANCER DRUGS
- Enhanced Antitumor Activity Induced by Adoptive T-Cell Transfer and Adjunctive Use of the Histone Deacetylase Inhibitor LAQ824
- (2009) D. D. Vo et al. CANCER RESEARCH
- Carboplatin and Paclitaxel in Combination With Either Vorinostat or Placebo for First-Line Therapy of Advanced Non–Small-Cell Lung Cancer
- (2009) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of nickel, chromate, and arsenite on histone 3 lysine methylation
- (2009) Xue Zhou et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
- (2008) D. S. Schrump et al. CLINICAL CANCER RESEARCH
- Loss of Histone H4K20 Trimethylation Occurs in Preneoplasia and Influences Prognosis of Non-Small Cell Lung Cancer
- (2008) A. Van Den Broeck et al. CLINICAL CANCER RESEARCH
- Histone Deacetylase 8 in Neuroblastoma Tumorigenesis
- (2008) I. Oehme et al. CLINICAL CANCER RESEARCH
- Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis
- (2008) Wilko Weichert et al. LANCET ONCOLOGY
- Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model
- (2008) A. Miyanaga et al. MOLECULAR CANCER THERAPEUTICS
- DNA Methylation Markers and Early Recurrence in Stage I Lung Cancer
- (2008) Malcolm V. Brock et al. NEW ENGLAND JOURNAL OF MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started